SEC Form 4 · accession 0001209191-16-125851
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Farah Champsi
Director
Period of report
Jun 1, 2016
Accepted (ET)
Jun 3, 2016 · 7:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2016 | A | 1,950 | $0.00 | A | 21,616 | D | |
| Common StockF1 | holding | — | — | — | 1,761,957 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F2 | $50.87 | Jun 1, 2016 | A | 7,000 | A | — | May 31, 2026 | Common Stock | 7,000 | 7,000 | D |
Explanation of responses
- F1The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.
- F2The stock option shall vest in 24 successive equal monthly installments following the date of grant.